Cancer vaccine prevents deadly melanoma from returning or spreading in landmark trial

Merck and Moderna announced that their mRNA cancer vaccine met its primary endpoint in a Phase 3 trial for melanoma patients. The vaccine demonstrated improved recurrence-free survival compared to a control group in patients who had undergone surgery. Results from the trial are expected to be presented at an upcoming medical conference or submitted for regulatory review.

Next story